Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MMP14 | P50281 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | TERT | O14746 | 4/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | CCR6 | P51684 | 1/20 | 0.46 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4296451 | 0.90 | MAOA (0.65) | MEN1KMT2AMMP14CYP1A2TSHR | |
| SCHEMBL4296856 | 0.88 | MAOA (0.57) | MEN1KMT2AMMP14MAOATERT | |
| SCHEMBL8426998 | 0.88 | MEN1 (0.65) | MEN1KMT2AMMP14CYP1A2TSHR | |
| SCHEMBL30544874 | 0.84 | MEN1 (0.82) | MEN1KMT2AMMP14CYP1A2TSHR | |
| SCHEMBL6419867 | 0.84 | MEN1 (0.82) | MEN1KMT2AMMP14CYP1A2TSHR | |
| SCHEMBL6422471 | 0.82 | MEN1 (0.65) | MEN1KMT2AMMP14CYP1A2TSHR | |
| SCHEMBL11139038 | 0.82 | MEN1 (0.58) | MEN1KMT2AMMP14CYP1A2TSHR | |
| SCHEMBL4299603 | 0.81 | MEN1 (0.64) | MEN1KMT2AMMP14CYP1A2TSHR | |
| SCHEMBL14600815 | 0.80 | MEN1 (0.76) | MEN1KMT2AMMP14CYP1A2TSHR | |
| SCHEMBL9174800 | 0.80 | MEN1 (0.76) | MEN1KMT2AMMP14CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163650-A1 | POLYMER MATERIAL | MENICON CO., LTD. (JP) | 2021-06-03 | — | — | US | disclosed |
| EP-3822296-A1 | POLYMER MATERIAL | Menicon Co., Ltd. (JP) | 2021-05-19 | — | — | EP | disclosed |
| US-20130202551-A1 | IONIC COMPOUND, COMPOSITION, CURED MATERIAL, HYDROGEL AND OPHTHALMIC LENS | MENICON CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| EP-2581394-A1 | IONIC COMPOUND, COMPOSITION, CURED PRODUCT, HYDROGEL, AND OCULAR LENS | Menicon Co., Ltd. (JP) | 2013-04-17 | — | — | EP | disclosed |
| EP-1696257-B1 | CONTACT LENS MATERIAL | MENICON CO LTD (JP) | 2012-11-21 | — | — | EP | disclosed |
| US-20090247662-A1 | Contact Lens Material | MATSUMOTO MASAHIRO | 2009-10-01 | — | — | US | disclosed |
| US-20070149699-A1 | Contact lens material | MENICON CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1696257-A1 | CONTACT LENS MATERIAL | MENICON CO., LTD. (JP) | 2006-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130202551-A1 | IONIC COMPOUND, COMPOSITION, CURED MATERIAL, HYDROGEL AND OPHTHALMIC LENS | CRYZ, CRYAA, VIL1 | MEN1 1583/4885KMT2A 3332/4885MMP14 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.